临床试验/PER-054-02

PER-054-02已完成未知

A RANDOMIZED, DOUBLE-BLIND, MULTICENTRIC STUDY TO EVALUATE THE TOLERABILITY AND EFFECTIVENESS OF ETORICOXIB 90 MG PER DAY, VS. SODIC DICLOFENACO 50 MG THREE TIMES A DAY IN PATIENTS WITH OSTEOARTHRITIS.

MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 0 人开始时间: 2002年8月19日最近更新: 2023年9月4日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•Patients who had a clinical diagnosis of osteoarthritis and who were to require, as expected, a chronic therapy with NSAIDs or a selective COX-2 inhibitor for at least 1 year were considered eligible to enter the study after signing. an informed consent.

排除标准

未提供

研究者

发起方

MERCK SHARP & DOHME PERU S.R.L.,

相似试验

A RANDOMIZED, DOUBLE-BLIND, MULTICENTRIC STUDY TO EVALUATE THE TOLERABILITY AND EFFECTIVENESS OF 90 MG ETORICOXIB ONCE A DAY COMPARED WITH 75 MG SODIUM DICLOFENACO TWICE A DAY IN PATIENTS WITH RHEUMATOID ARTHRITIS.-M06M06

PER-011-03MERCK & CO.INC.,

A RANDOMIZED, DOUBLE-BLIND, MULTICENTRIC STUDY OF ZOLEDRONIC ACID (4 MG AND 8 MG) ADMINISTERED INTRAVENOUSLY TO PATIENTS WITH RECIDIVAL OR REFRACTORY HYPERCALCEMIA, INDUCED BY NEOPLASIA.-E835 Disorders of calcium metabolismDisorders of calcium metabolismE835

PER-062-02OVARTIS BIOSCIENSES PERU S.A.,

A DOUBLE-BLIND, RANDOMIZED, MULTI-CENTRAL STUDY OF 3 PERIODS, CROSSED TO EVALUATE THE EFFECTS OF A SINGLE DOSE OF MONTELUKAST COMPARED TO THE PLACEBO AND SALMETEROL IN BRONCHOCONSTRICTION INDUCED BY EXERCISE-J45J45

PER-059-05MERCK & CO.INC.,

A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS TO ORAL SOLITHROMYCIN (CEM-101) COMPARED TO INTRAVENOUS TO ORAL MOXIFLOXACIN IN THE TREATMENT OF ADULT PATIENTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA.-J159 Bacterial pneumonia, unspecifiedBacterial pneumonia, unspecifiedJ159

PER-028-14Cempra Pharmaceuticals, Inc.,9

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO COMPARE THE EFFICACY AND SAFETYOF CADAZOLID VERSUS VANCOMYCIN IN SUBJECTS WITH CLOSTRIDIUM DIFFICILE-ASSOCIATEDDIARRHEA (CDAD)-A047 Enterocolitis due to Clostridium difficileEnterocolitis due to Clostridium difficileA047

PER-087-13Actelion Pharmaceuticals Ltd,1